Psoriasis Comorbidities at Hospital Calderón Guardia
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
- Кому может быть актуально
- Состояния в реестре: Psoriasis, Psoriasis Arthritis, Psoriasis (PsO), Psoriasis Patients. Базовые параметры: от 12 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Costa Rica
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Prevalence of Metabolic Comorbidities, Atherosclerotic Arterial Disease, and Psoriatic Arthritis in Patients With Psoriasis and Their Association With Clinical Severity and Therapeutic Profile Among Patients Treated at Hospital Rafael Ángel Calderón Guardia During 2024-2025
Обзор
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are: What are the demographic and clinical characteristics and severity profiles of psoriasis patients? What treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes? Patients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.
Подробное описание
Psoriasis is a chronic immune-mediated inflammatory dermatosis with variable severity, systemic associations, and substantial quality-of-life impact. Although multiple topical, phototherapy, systemic, and biologic treatments are available, real-world epidemiologic and therapeutic data in Costa Rica remain limited. This study is a retrospective observational characterization of psoriasis patients treated between 2024 and 2025. Unlike interventional trials evaluating specific drugs or prospective registries of targeted therapies, this study analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI), comorbidities, and treatment patterns across routine care. It does not introduce therapeutic modifications or standardized follow-up, but reflects real-world management decisions across disease severities. By capturing population-level data on psoriasis presentation and treatment in Costa Rica, the study provides baseline national evidence distinct from drug-specific or interventional psoriasis studies.
Первичные конечные точки
- Prevalence of Metabolic Comorbidities in Patients With Psoriasis [Срок оценки: 2024-2025]
- Prevalence of Atherosclerotic Cardiovascular Disease [Срок оценки: 2024-2025]
- Prevalence of Psoriatic Arthritis [Срок оценки: 2024-2025]
Вторичные конечные точки (4)
- Psoriasis Severity [Срок оценки: 2024-2025]
- Psoriasis Severity [Срок оценки: 2024-2025]
- Association Between Psoriasis Severity and Comorbidities [Срок оценки: 2024-2025]
- Inflammatory and Metabolic Biomarkers [Срок оценки: 2024-2025]
Критерии участия
Критерии включения
- Patients evaluated in outpatient clinics during the period 2024-2025.
- Patients receiving systemic therapy and/or phototherapy.
- Patients aged 12 years or older, of any sex.
- Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis.
- At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period.
- Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.
Критерии исключения
- Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile.
- Patients managed exclusively with topical therapies.
- Duplicate or inconsistent records, preventing accurate patient classification.
- Cutaneous conditions not compatible with psoriasis.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
Costa Rica · 1 центр
- Caja Costarricense del Seguro Social — San José
Идентификаторы
NCT: NCT07448337 · CEC HCG 03-2026